BioForce Nanosciences Reports No Revenue and Increased Losses in Q2 2025

BioForce Nanosciences Holdings, Inc. reported its financial results for the second quarter and first half of 2025, revealing a continued lack of revenue generation. For the three months ended June 30, 2025, the company reported no sales, consistent with the same period in 2024. The net loss for the quarter was $122,781, compared to a loss of $114,440 in the prior year. For the six months ended June 30, 2025, the net loss increased significantly to $1,057,431 from $245,253 in the same period of 2024, largely due to a loss on liability settlement amounting to $801,193.

The company's total assets as of June 30, 2025, were $905, a slight increase from $862 at the end of 2024. However, total liabilities decreased significantly to $384,928 from $2,302,454, primarily due to a reduction in accrued expenses and liabilities owed to related parties. The accumulated deficit also grew to $162,177,597, reflecting ongoing operational challenges. The company’s stockholders’ deficit improved to $384,023 from $2,301,592, attributed to the issuance of 4,250,000 shares to settle liabilities.

Operationally, BioForce has not reported any sales of its BioForce Eclipse vitamin supplements, which it markets through various channels, including social media and telemarketing. The company is in the process of establishing a more dynamic marketing campaign to enhance brand awareness and drive sales. Despite these efforts, the lack of revenue generation remains a critical concern, as the company continues to rely on loans from its officers to cover operational expenses.

Looking ahead, BioForce Nanosciences Holdings, Inc. acknowledges the need for additional capital to support its business plan and operations. The management has indicated that without sufficient revenue, the company may face challenges in continuing its operations or may need to alter its business model. The company is actively seeking to expand its market presence and product offerings, particularly in the nutritional supplement sector, but faces significant hurdles in achieving profitability.

In summary, BioForce Nanosciences Holdings, Inc. continues to navigate a challenging financial landscape with no revenue generation reported for the first half of 2025. The company is focused on enhancing its marketing strategies and expanding its product reach, while also addressing its financial viability through potential capital raises and operational adjustments.